Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.2K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

482
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
482
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

311
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
311
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

163
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
163
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

261
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
261
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

PharmacoEconomics·2025
Same author

Service delivery, behavioural, and self-management interventions for children with epilepsy.

The Cochrane database of systematic reviews·2025
Same author

Prognostic factors predicting an unprovoked seizure recurrence in children and adults following a first unprovoked seizure.

The Cochrane database of systematic reviews·2025
Same author

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.

Blood advances·2025
Same author

Service delivery, behavioural, and self-management interventions for adults with epilepsy.

The Cochrane database of systematic reviews·2025
Same author

Antiseizure medications for preventing a first seizure in adults with a brain tumour.

The Cochrane database of systematic reviews·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Aug 30, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

9.9K

Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Angela E Rankine-Mullings1, Sarah J Nevitt2

  • 1Sickle Cell Unit, Caribbean Institute for Health Research, University of the West Indies, Kingston, Jamaica.

The Cochrane Database of Systematic Reviews
|September 1, 2022
PubMed
Summary
This summary is machine-generated.

Hydroxyurea may effectively reduce pain episodes and acute complications in sickle cell disease (SCD) patients with HbSS or HbSβºthal genotypes. However, more research is needed on its long-term benefits, risks, and effects on different SCD genotypes.

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Related Experiment Videos

Last Updated: Aug 30, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

9.9K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Area of Science:

  • Hematology
  • Pharmacology
  • Genetics

Background:

  • Sickle cell disease (SCD) is a prevalent inherited disorder causing significant morbidity and reduced lifespan.
  • Hydroxyurea (hydroxycarbamide) is an oral chemotherapeutic agent that can alleviate SCD symptoms by increasing fetal hemoglobin (HbF).
  • This review updates previous findings on hydroxyurea's efficacy and safety in SCD management.

Purpose of the Study:

  • To evaluate the impact of hydroxyurea on acute events, organ dysfunction, mortality, and quality of life in individuals with SCD.
  • To assess potential variations in hydroxyurea response based on SCD type, patient age, treatment duration, dosage, and healthcare setting.
  • To identify any associated adverse effects of hydroxyurea treatment in SCD patients.

Main Methods:

  • Systematic review of randomized and quasi-randomized controlled trials (RCTs) of at least one month's duration.
  • Searches conducted across multiple databases, including the Cochrane Haemoglobinopathies Register and online trial registries, up to February 17, 2022.
  • Independent assessment of study inclusion, data extraction, risk of bias, and quality of evidence (GRADE) by authors.

Main Results:

  • Hydroxyurea likely improves pain management and reduces life-threatening illnesses in HbSS and HbSβºthal genotypes, with moderate-quality evidence.
  • Evidence suggests hydroxyurea may increase HbF levels and decrease neutrophil counts, though quality of life and adverse event data were limited.
  • Limited evidence exists for hydroxyurea's effectiveness in HbSC genotype and for long-term outcomes or optimal dosing strategies.

Conclusions:

  • Hydroxyurea shows potential in reducing pain crises and acute complications for specific SCD genotypes (HbSS, HbSβºthal).
  • It may also prevent neurological events in individuals at risk of stroke.
  • Further research is crucial to establish long-term benefits, risks, optimal dosing, and efficacy across all SCD genotypes.